Prelude Therapeutics INC 8-K filings
NASDAQ
Prelude Therapeutics announced its full year 2023 financial results, highlighting progress in its clinical programs and outlining key objectives for 2024, including advancing its SMARCA2 degrader and CDK9 inhibitor programs.